TORONTO, Nov. 8, 2024
/CNW/ - Auxly Cannabis Group Inc. (TSX: XLY) (OTCQB:
CBWTF) ("Auxly" or the "Company") a leading
consumer packaged goods company in the cannabis products market,
today released its financial results for the three and nine months
ended September 30, 2024. These
filings and additional information regarding Auxly are available
for review on SEDAR+ at www.sedarplus.ca.
Q3 2024 Highlights and Subsequent
Events
- The Company continues to outperform, delivering another
record-breaking quarter of financial results across key metrics of
revenue, margin and adjusted EBITDA;
- Established a new all-time record in net revenues of
$33.3 million, an increase of 18%
year-over-year and 14% quarter-over-quarter;
- Set a new all-time record in Gross Margin on Finished Cannabis
Inventory Sold1 of 47% in the quarter, an improvement of
17% year-over-year;
- SG&A continued to remain substantially flat
quarter-over-quarter, with a notable 16% decrease
year-over-year;
- Fifth consecutive quarter of positive adjusted
EBITDA1, achieving a new all-time record of $8.3 million, representing a 60%
quarter-over-quarter increase and a remarkable 6,982% increase
compared to the same period in 2023;
- Net income of $3.2 million and
cash flow provided by operating activities of $12.9 million;
- The Company continued to make improvements to its balance sheet
by reducing its debt1, by 54% compared to the end of
2023, including repaying the outstanding principal on the Company's
standby financing facility;
- The Company saw improvements in its overall national market
share, moving into the #4 LP position in national recreational
sales for the quarter2;
- Market leadership in the all-in-one vape category,
securing over 36% of the total market share in the category and 50%
of the top 10 vape SKU positions nationally;
- Back Forty's Liquid Imagination 28g SKU continued to win
with consumers, ending the quarter as the #1 selling flower
nationally;
- The Company's pre-roll product suite saw a 19% increase in
national sales compared to the previous quarter with Back Forty's
Wedding Pie and Banana OG, securing the #3 and #4 position
respectively, in national non-infused pre-roll sales for the
quarter.
___________________________________
|
1 Non-IFRS
or Supplementary financial measure. Refer to the Non-GAAP
Measures section in the MD&A for definitions.
|
2 Hifyre IQ
as of October 23, 2024.
|
FINANCIAL HIGHLIGHTS AND KEY PERFORMANCE INDICATORS
For the three months
ended:
(000's)
|
September
30,
2024
|
September 30,
2023
|
Change
|
% Change
|
Net revenues
|
$
33,284
|
$
28,211
|
$
5,073
|
18 %
|
Gross margin on
finished cannabis inventory sold*
|
15,559
|
8,593
|
6,966
|
81 %
|
Gross margin on
finished cannabis inventory sold (%)*
|
47 %
|
30 %
|
17 %
|
57 %
|
Net
income/(loss)
|
3,239
|
32,621
|
(29,382)
|
-90 %
|
Adjusted
EBITDA*
|
8,286
|
117
|
8,169
|
6,982 %
|
Weighted Average Shares
outstanding - basic
|
1,265,144,208
|
1,002,068,656
|
263,075,552
|
26 %
|
For the nine months
ended:
(000's)
|
September
30,
2024
|
September 30,
2023
|
Change
|
% Change
|
Net revenues
|
$
87,703
|
$
74,169
|
$
13,534
|
18 %
|
Gross margin on
finished cannabis inventory sold*
|
37,177
|
23,491
|
13,686
|
58 %
|
Gross margin on
finished cannabis inventory sold (%)*
|
42 %
|
32 %
|
10 %
|
31 %
|
Net
income/(loss)
|
(20,771)
|
9,509
|
(30,280)
|
-318 %
|
Adjusted
EBITDA*
|
15,699
|
(823)
|
16,522
|
2,008 %
|
Weighted Average Shares
outstanding - basic
|
1,177,818,866
|
986,208,447
|
191,610,419
|
19 %
|
|
|
|
|
|
|
|
|
|
|
As
at: (000's)
|
September
30,
2024
|
December 31,
2023
|
Change
|
% Change
|
Cash and
equivalents
|
$
18,957
|
$ 15,608
|
$
3,349
|
21 %
|
Total assets
|
264,224
|
261,904
|
2,320
|
1 %
|
Debt
|
57,259
|
123,579
|
(66,320)
|
-54 %
|
*Non-IFRS or
supplementary financial measure. Refer to the Non-GAAP
Measures section in the MD&A for definitions
|
Hugo Alves, CEO of Auxly, commented:
"Our continued focus on efficient revenue growth and enhanced
profitability has delivered another record-breaking quarter of
financial results, highlighted by an 18% year-over-year increase in
net revenue and record adjusted EBITDA of $8.3 million. Our commitment to providing
consumers with exceptional products that help them live happier
lives enabled us to grow national market share in our core product
categories of dried flower, pre-rolls and vapes; and has elevated
Back Forty to the #1 brand in Ontario by dollars sold. We remain focused on
creating long-term shareholder value. I am excited for the future
and proud of the tremendous efforts of our talented and dedicated
team in delivering these results."
RESULTS OF OPERATIONS
For the periods ended:
|
Three months
September 30,
|
Nine months
September 30,
|
(000's)
|
2024
|
2023
|
2024
|
2023
|
Revenue
Revenue from sales of
cannabis products
Excise
taxes
|
$
50,994
|
$
39,910
|
$
132,784
|
$
111,968
|
|
(17,710)
|
(11,699)
|
(45,081)
|
(37,799)
|
Total Net
Revenues
|
33,284
|
28,211
|
87,703
|
74,169
|
Cost of Sales
Costs of finished
cannabis inventory sold
Inventory
impairment
|
17,725
674
|
19,618
3,233
|
50,526
1,603
|
50,678
5,365
|
Gross
profit/(loss) excluding fair value items
|
14,885
|
5,360
|
35,574
|
18,126
|
|
|
Unrealized fair value
gain/(loss) on biological transformation
Realized fair value
gain/(loss) on inventory
|
9,964
(7,703)
|
4,766
(5,538)
|
21,554
(14,602)
|
13,726
(13,323)
|
Gross
Profit
|
17,146
|
4,588
|
42,526
|
18,529
|
|
Expenses
Selling, general, and
administrative expenses
Equity-based
compensation
Depreciation and
amortization
Interest and
accretion expenses
|
8,457
1,324
1,197
3,133
|
10,016
707
1,817
6,613
|
26,389
3,952
3,494
12,750
|
28,916
1,493
5,235
18,878
|
Total expenses
|
14,111
|
19,153
|
46,585
|
54,522
|
Other income/(loss)
Interest and other
income
Impairment of
assets
Gain/(loss) on
settlement of assets and liabilities and other expenses
Gain/(loss) on
disposal of assets held for sale
Foreign exchange
gain/(loss)
|
54
-
183
-
(33)
|
16
-
46,887
-
283
|
213
-
(60)
(453)
(420)
|
10
(2,588)
48,365
-
(285)
|
Total other
income/(loss)
|
204
|
47,186
|
(720)
|
45,502
|
|
Net income/(loss) before income
tax
Income tax
recovery/(expense)
|
3,239
-
|
32,621
-
|
(4,779)
(15,992)
|
9,509
-
|
Net income/(loss)
|
$
3,239
|
$
32,621
|
$ (20,771)
|
$
9,509
|
Adjusted EBITDA
|
$
8,286
|
$ 117
|
$
15,699
|
$
(823)
|
Net income/(loss) per common share – basic
($)
|
$
0.00
|
$
0.03
|
$ (0.02)
|
$ 0.01
|
Net income/(loss) per common share – diluted
($)
|
$
0.00
|
$
0.03
|
$ (0.02)
|
$
0.01
|
Weighted average shares outstanding –
basic
|
1,265,144,208
|
1,002,068,656
|
1,177,818,866
|
986,208,447
|
Weighted average shares outstanding -
diluted
|
1,347,922,412
|
1,002,068,656
|
1,177,818,866
|
986,208,447
|
Revenue
For the three and nine months ended September 30, 2024, net revenues were
$33.3 million and $87.7 million as compared to $28.2 million and $74.2
million during the same period in 2023, representing
increases of 18%. Revenues for the three and nine months ended
September 30, 2024 were comprised of
approximately 59% (2023 – 67%) and 60% (2023 – 61%) in sales of
dried flower and pre-roll Cannabis Products, with the remainder
from oils and Cannabis 2.0 Product sales.
For the three and nine months ended September 30, 2024, approximately 76% (2023 –
81%) and 77% (2023 – 84%) of cannabis sales originated from sales
to British Columbia, Alberta and Ontario.
Gross Profit
Auxly realized a gross profit of $17.1
million and $42.5 million for
the three and nine months ended September
30, 2024, resulting in a 52% and 48% Gross Profit Margin,
respectively as compared to $4.6
million (16%) and $18.5
million (25%) during the same periods in 2023. The Gross
Margin on Finished Cannabis Inventory Sold for the three months
ended September 30, 2024 improved to
47% versus 30% in the same period of 2023 as a result of the
streamlining and improvements made in our manufacturing process to
reduce operating costs and increased demand and pricing of bulk
flower product.
Realized and unrealized fair value gains and losses reflect
accounting treatments associated with Auxly Leamington cultivation
activities and sales and are influenced by changes in production,
sales and net realizable value assumptions.
Inventory impairments during the third quarter of 2024 of
$0.7 million were associated with
charges related to the obsolescence of certain retired products, a
decrease of $2.6 million from the
comparative period.
Total Expenses
Selling, general and administrative expenses ("SG&A") are
comprised of wages and benefits, office and administrative,
professional fees, business development, and selling expenses.
SG&A expenses were $8.5 million
in the third quarter of 2024, $1.6
million or 16% lower than the same period in 2023.
Year-to-date expenditures of $26.4
million in 2024 were $2.5
million lower than the same period in 2023. The decrease in
SG&A was primarily as a result of measures taken to reduce
overhead in the organization.
Wages and benefits were $3.9
million for the third quarter of 2024, as compared to
$4.0 million for the same period of
2023. Year-to-date expenditures of $13.0
million were higher than that of $11.9 million during the same period in 2023. The
increase in expenses year-to-date was related to non-recurring
restructuring related costs that were partially offset by the
decrease in expenses related to the streamlining of operations and
support staff as a result of a more focused product portfolio.
Office and administrative expenses were $1.2 million for the third quarter of 2024,
$1.5 million lower than the same
period in 2023. Year-to-date expenditures of $3.7 million were lower than that of $8.1 million during the same period in 2023. The
decreased expenditures were primarily related to streamlining of
operations, the transition of the Company's dried flower and
pre-roll cannabis product manufacturing, processing and
distribution activities to the Auxly Leamington facility, and
reduced insurance expenses.
Auxly's professional fees were $0.5
million during the third quarter of 2024, $0.5 million lower than the same period in 2023.
Year-to-date expenditures of $1.4
million were $1.0 million
lower than the same period in 2023. Professional fees incurred
primarily related to accounting fees, regulatory matters, reporting
issuer fees, and legal fees associated with certain corporate
activities and as a result can fluctuate significantly from one
period to the next.
Business development expenses were $0.3
million for the nine months ended September 30, 2024, $0.1
million lower than the same period in 2023. These expenses
primarily relate to business development and travel related
expenses.
Selling expenses were $2.8 million
and $8.0 million for the three and
nine months ended September 30, 2024,
an increase of $0.5 million and
$1.8 million from the same periods in
2023, respectively. The increase in expenditures was primarily as a
result of investments in marketing initiatives and higher Health
Canada fees related to higher revenues.
Equity-based compensation for the three and nine months ended
September 30, 2024 was $1.3 million and $4.0
million, respectively, primarily due to the impact of the
increased closing price of the Company's Shares as at September 30, 2024 on the value of Cash Settled
RSUs granted in 2023. During the same periods of 2023, equity-based
compensation was $0.7 million and
$1.5 million, respectively.
Depreciation and amortization expenses were $1.2 million for the third quarter of 2024 and
$3.5 million year-to-date,
representing a decrease of $0.6
million and $1.7 million over
the same periods in 2023. The decreases were primarily as a result
of reductions in intangible assets and depreciation associated with
disposed assets, including the transition out of the Auxly Ottawa
Carleton Place facility.
Interest expenses were $3.1
million and $12.8 million for
the three and nine months ended September
30, 2024, a decrease of $3.5
million and $6.1 million over
the same periods in 2023. The decrease in expenses were primarily a
result of the conversion of Imperial Debentures into Shares and
lower interest expense on adjustable-rate debt, partially offset by
interest from newly financed obligations. Interest expense includes
accretion on the convertible debentures and interest paid in kind
on the Imperial Debenture. Interest payable in cash was
approximately $2.4 million for the
third quarter of 2024, flat to the same period in 2023.
Total Other Incomes and Losses
Total other incomes and losses was a net gain of $0.2 million for the third quarter of 2024 and a
net loss of $0.7 million
year-to-date, compared to net gains of $47.2
million and $45.5 million in
the comparative periods. The year-to-date other incomes and losses
included the loss on the adjustment to the provision related to the
claim filed by Kindred Partners Inc., the loss on the sale of the
Auxly Ottawa facility, partially offset by the gains on the
extensions of the unsecured promissory notes. The net gains in 2023
were primarily driven by the gains on the extension of the maturity
of the Imperial Brands Debenture, partially offset by the closure
of the Auxly Ottawa facility where the carrying value exceeded the
fair value less cost to sell.
Net Income and Loss
Net income for the three months ended September 30, 2024 was $3.2 million, representing a net income of $nil
per share on a basic and diluted basis. Excluding the gains on the
extension of the Imperial Brands Debenture in the third quarter of
2023 of $46.9 million, net income
increased by $17.5 million, primarily
driven by improved gross profits and reduction in expenses. The net
loss of $20.8 million for the nine
months ended September 30, 2024
included $16.0 million of deferred
tax expense on the conversion of Imperial Debenture into
Shares.
Adjusted EBITDA
Adjusted EBITDA was $8.3 million
and $15.7 million for the three and
nine months ended September 30,
2024, an improvement of $8.2
million and $16.5 million over
the same period of 2023, primarily as a result of improvements in
gross profits and reductions in SG&A.
Outlook
In 2024, Auxly remains dedicated to sustainable growth, improved
profitability, and the excellence of its people. The Company will
prioritize focused and efficient growth in its key product
categories of vape, pre-roll and dried flower and continue to
optimize and improve distribution and sales of its products. The
Company will continue to foster a collaborative team environment
and pursue continued improvements in efficiency to reduce costs and
deliver strong gross margins and increased profitability. The
Company will also continue to pursue opportunities to strengthen
its balance sheet.
The continued execution against the Company's strategy has
delivered the best quarter in Auxly's history across all key
metrics. Building off the momentum from the first half of 2024,
Auxly increased both revenue and profits in this quarter and gained
overall market share in the adult recreational market exiting Q3 as
the 4th largest licensed producer in Canada by retail sales3. The
improvements in Company performance were driven by higher sales
volumes in its core product categories and continued cost
discipline. Dried flower retail sales increased by over 12%
compared to the previous quarter with its Back Forty Liquid
Imagination 28g SKU securing the #3 SKU nationally, an improvement
from its top 10 SKU position in the previous quarter. In the hyper
competitive vape category, Auxly branded products represented
approximately 50% of the top 10 vape SKU's nationally, driven by
the continued dominance of the Company's products within the
all-in-one vape segment. Auxly's pre-roll retail sales increased by
nearly 19% quarter over quarter which was led by the consumer
favourite Back Forty branded product suite. Looking ahead, Auxly
will continue to drive revenue performance with product innovation
in its core product formats, deepen relationships with key account
retailers and expand product distribution.
The shift in product mix towards the Company's core categories
and continued operational improvements contributed to the higher
gross profits in the quarter, reflecting a 47% Finished Cannabis
Inventory Sold Margin compared to 30% in the comparative period.
The successful execution of the Company's previously disclosed
efforts to increase cultivation yields also contributed to the
improved gross margin, as the Company efficiently increased yields,
thereby resulting in a lower cost of goods sold. The Company
remained disciplined in its spending and capital management. The
Company successfully reduced overhead across the organization,
ending the third quarter with $8.5
million in SG&A expenses. This is 16% lower than the
comparative period in 2023 and lower than the second quarter of
this year. Looking ahead, Auxly will remain focused on
enhancing operational efficiency; enabling it to set new industry
benchmarks for profitability while continuing to deliver
sustainable growth.
Auxly's low-cost cultivation is a competitive advantage within
the current Canadian cannabis landscape. With only a few
large-scale greenhouses capable of consistently producing high
quality cannabis at a low cost, the Company is seeing increased
demand and pricing for its bulk flower products. Given the
significant capital outlay and amount of time necessary to
replicate the scale, automation, consistency, and efficiency of its
Auxly Leamington facility, the Company believes that Auxly
Leamington provides it with a significant competitive advantage
from competition in the short and medium term. The Company intends
to leverage this advantage to drive further growth in the Canadian
adult-use market and in wholesale bulk cannabis sales to other
industry participants.
Importantly, the Company also took steps this quarter to
continue strengthening its balance sheet. Auxly repaid the
outstanding principal on the standby financing facility in
August 2024 and subsequent to
quarter-end, it extended the maturity date of the inventory
financing loan to October 2025. Balance sheet improvement
will continue to be a key area of focus for the Company with the
goal of lowering overall debt and cost of capital.
Looking ahead, the Company will continue to prioritize efficient
growth and sustainable profitability, driven by the excellence of
its people, increased consumer demand for its quality products, an
exciting pipeline of innovative new products and its commitment to
continued improvement in operational efficiency and overhead cost
management.
_____________________________
|
3 HiFyre IQ
as at October 23, 2024.
|
Non- GAAP Measures
Please see the Company's MD&A dated November 7, 2024, under "Non-GAAP Measures" for a
further description of the following financial and supplementary
financial measures.
Financial Measures
EBITDA and Adjusted EBITDA
These are non-GAAP measures used in the cannabis industry and by
the Company to assess operating performance removing the impacts
and volatility of non-cash and other adjustments. The definition
may differ by issuer. The Adjusted EBITDA reconciliation is as
follows:
(000's)
|
Q4/22
|
Q1/23
|
Q2/23
|
Q3/23
|
Q4/23
|
Q1/24
|
Q2/24
|
Q3/24
|
Net
income/(loss)
|
$
(16,056)
|
$
(10,249)
|
$
(12,863)
|
$
32,621
|
$
(54,020)
|
$(26,012)
|
$
2,002
|
$
3,239
|
Interest and accretion
expense
|
5,655
|
5,808
|
6,457
|
6,613
|
6,837
|
6,868
|
2,749
|
3,133
|
Interest and other
income
|
(63)
|
(14)
|
20
|
(16)
|
(22)
|
(19)
|
(140)
|
(54)
|
Income tax
expense/(recovery)
|
(1,112)
|
-
|
-
|
-
|
(3,238)
|
15,992
|
-
|
-
|
Depreciation and
amortization
included in cost of sales
|
1,296
|
1,120
|
911
|
1,151
|
1,084
|
1,292
|
1,780
|
1,382
|
Depreciation and
amortization
included in expenses
|
2,791
|
1,745
|
1,673
|
1,817
|
1,708
|
1,230
|
1,067
|
1,197
|
EBITDA
|
(7,489)
|
(1,590)
|
(3,802)
|
42,186
|
(47,651)
|
(649)
|
7,458
|
8,897
|
|
|
|
|
|
|
|
|
|
Impairment of
inventory
|
2,062
|
673
|
1,459
|
3,233
|
5,109
|
456
|
473
|
674
|
Unrealized fair
value
loss/(gain) on biological
transformation
|
(2,814)
|
(4,247)
|
(4,713)
|
(4,766)
|
(2,481)
|
(2,773)
|
(8,817)
|
(9,964)
|
Realized fair value
loss/(gain)
on inventory
|
7,382
|
4,639
|
3,146
|
5,538
|
5,428
|
2,435
|
4,464
|
7,703
|
Restructuring related
costs
|
-
|
165
|
86
|
29
|
131
|
-
|
655
|
(75)
|
Equity-based
compensation
|
429
|
409
|
377
|
707
|
148
|
1,927
|
701
|
1,324
|
Impairment of
assets
|
676
|
-
|
2,588
|
-
|
37,118
|
-
|
-
|
-
|
Non-recurring bad
debt
expense/(recovery)
|
-
|
-
|
780
|
360
|
-
|
-
|
-
|
(123)
|
(Gain)/loss on
settlement of
assets, liabilities and disposals
|
(1,330)
|
-
|
(1,478)
|
(46,887)
|
4,006
|
634
|
62
|
(183)
|
Foreign exchange
loss/(gain)
|
301
|
89
|
479
|
(283)
|
486
|
210
|
177
|
33
|
Adjusted
EBITDA
|
$ (783)
|
$
138
|
$
(1,078)
|
$
117
|
$ 2,294
|
$
2,240
|
$
5,173
|
$
8,286
|
Supplementary Financial Measures
Gross Margin on Finished Cannabis Inventory Sold
"Gross Margin on Finished Cannabis Inventory Sold" is a
supplementary financial measure and is defined as net revenues less
cost of finished cannabis inventory sold divided by net
revenues.
Gross Profit Margin
"Gross Profit Margin" is defined as gross profit divided by net
revenues. Gross Profit Margin is a supplementary financial
measure.
Debt
"Debt" is defined as current and long-term debt and is a
supplementary financial measure. It is a useful measure in managing
the Company's capital structure and financing requirements.
ON BEHALF OF THE BOARD
"Hugo Alves" CEO
About Auxly Cannabis Group Inc. (TSX: XLY)
Auxly is a leading Canadian consumer packaged goods company in
the cannabis products market, headquartered in Toronto, Canada. Our mission is to help
consumers live happier lives through quality cannabis products that
they trust and love.
Our vision is to be a leader in branded cannabis products that
deliver on our consumer promise of quality, safety and
efficacy.
Learn more at www.auxly.com and stay up to date at Twitter:
@AuxlyGroup; Instagram: @auxlygroup; Facebook:
@auxlygroup; LinkedIn: company/auxlygroup/.
Notice Regarding Forward Looking Information:
This news release contains certain "forward‐looking information"
within the meaning of applicable Canadian securities law.
Forward‐looking information is frequently characterized by words
such as "plan", "continue", "expect", "project", "intend",
"believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or information that certain
events or conditions "may" or "will" occur. This information is
only a prediction. Various assumptions were used in drawing the
conclusions or making the projections contained in the
forward‐looking information throughout this news release.
Forward‐looking information includes, but is not limited to: the
proposed operation of Auxly, its subsidiaries and
partners; the intention to grow the business, operations and
existing and potential activities of Auxly; proposed timelines
for the build‐out, expansion, licencing or commercialization of the
Company's facilities and projects; the Company's execution of
its innovative product development, commercialization strategy and
expansion plans; the Company's intention to introduce innovative
new cannabis products to the market and the timing thereof; the
anticipated benefits of the Company's partnerships, research and
development initiatives and other commercial arrangements;
expectations regarding the anticipated benefits of the Imperial
Debt Conversion; the expectation, timing and quantum of future
revenues, Gross Margin on Finished Cannabis Inventory Sold,
SG&A and of positive Adjusted EBITDA; expectations regarding
the Company's expansion of sales, operations and investment
into foreign jurisdictions; future legislative and
regulatory developments involving
cannabis and cannabis
products; the timing and outcomes
of regulatory or intellectual property decisions; the ability
of the Company to maintain and grow its market share; the relevance
of Auxly's subsidiaries'
current and proposed products with provincial
purchasers and
consumers; consumer preferences; political change; competition and other risks affecting the
Company in particular and the cannabis industry
generally.
A number of factors could cause actual
results to differ
materially from a conclusion, forecast
or projection contained in the forward‐looking
information in this release including, but not limited to, whether:
the Company will be able to execute on its business strategy
or achieve its goals; Auxly's subsidiaries are able to maintain the
necessary governmental and regulatory authorizations to conduct
business; the Company is able to successfully manage
the integration of its various business units with its own; the
Company's subsidiaries obtain and maintain all
necessary governmental and regulatory permits and approvals for the
operation of their facilities and the development of cannabis
products, and whether such permits and approvals can be
obtained in a timely manner; the expected benefits of the Imperial
Debt Conversion materialize in the manner expected, or at all; the
expected benefits of the Auxly Leamington credit facility amendment
agreement materialize in the manner expected, or at all; the
Company will be able to successfully launch new product formats and
enter into new markets; there is acceptance and demand for current
and future Company products by consumers and provincial
purchasers; the Company will be able to increase and maintain
revenues, maintain positive Adjusted EBITDA, and/or achieve and
maintain its target Gross Margin on Finished Cannabis Inventory
Sold; and general economic, financial market, legislative,
regulatory, competitive and political conditions in which the
Company and its subsidiaries and partners operate will remain the
same. Additional risk factors are disclosed in the annual
information form of the Company for the financial year ended
December 31, 2023 dated March 24, 2024.
New factors emerge from time to time, and it is not possible for
management to predict all of those factors or to assess in advance
the impact of each such factor on the Company's business or the
extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any
forward‐looking information. The forward‐looking information in
this release is based on information currently available and what
management believes are reasonable assumptions. Forward‐ looking
information speaks only to such assumptions as of the date of this
release. In addition, this release may contain forward‐looking
information attributed to third party industry sources, the
accuracy of which has not been verified by the Company. The
forward‐looking information is being provided for the purposes of
assisting the reader in understanding the Company's financial
performance, financial position and cash flows as at and for
periods ended on certain dates and to present information about
management's current expectations and plans relating to the future,
and the reader is cautioned that such forward‐ looking information
may not be appropriate for any other purpose. Readers should not
place undue reliance on forward‐looking information contained in
this release.
The forward‐looking information contained in this release is
expressly qualified by the foregoing cautionary statements and is
made as of the date of this release. Except as may be required by
applicable securities laws, the Company does not undertake any
obligation to publicly update or revise any forward‐ looking
information to reflect events or circumstances after the date of
this release or to reflect the occurrence of unanticipated events,
whether as a result of new information, future events or results,
or otherwise.
Neither Toronto Stock Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the
Toronto Stock Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/auxly-reaches-new-financial-milestones-in-record-breaking-q3-2024-and-grows-overall-national-market-share-302299793.html
SOURCE Auxly Cannabis Group Inc.